{"entity":{"id":"alexis-cortot","kind":"person","name":"Alexis Cortot","aka":[],"tldr":"Lille pulmonologist and thoracic oncologist who presides over the IFCT, France's academic lung cancer trials group.","summary":"Alexis Cortot is President of the Intergroupe Francophone de Cancérologie Thoracique (IFCT), elected at the June 2025 general assembly. He is a pulmonologist at Lille University Hospital whose research covers targeted therapy and immunotherapy for non-small cell lung cancer. The IFCT runs multicentre academic trials in thoracic oncology across France and francophone countries.","asOf":"2026-09-10","links":[{"label":"Society page","url":"https://www.ifct.fr/a-propos-de-l-ifct/conseil-d-administration"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Cortot+AB%5BAuthor%5D"}],"tags":["leadership","clinician-scientist","lung cancer","clinical trials"],"related":[],"cancers":["nsclc","sclc"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["ifct"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"President","institutionId":"ifct","specialisms":["Thoracic oncology","Lung cancer","Pulmonology"],"profiles":[{"label":"Society page","url":"https://www.ifct.fr/a-propos-de-l-ifct/conseil-d-administration"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Cortot+AB%5BAuthor%5D"}],"papers":[{"title":"First-Line Afatinib plus Cetuximab for EGFR -Mutant Non–Small Cell Lung Cancer: Results from the Randomized Phase II IFCT-1503 ACE-Lung Study","journal":"Clinical Cancer Research","year":2021,"doi":"10.1158/1078-0432.ccr-20-4604"},{"title":"Weekly paclitaxel plus bevacizumab versus docetaxel as second- or third-line treatment in advanced non-squamous non–small-cell lung cancer: Results of the IFCT-1103 ULTIMATE study","journal":"European Journal of Cancer","year":2020,"doi":"10.1016/j.ejca.2020.02.022"},{"title":"Combination of Trastuzumab, Pertuzumab, and Docetaxel in Patients With Advanced Non–Small-Cell Lung Cancer Harboring HER2 Mutations: Results From the IFCT-1703 R2D2 Trial","journal":"Journal of Clinical Oncology","year":2022,"doi":"10.1200/jco.21.01455"}],"orcid":"0000-0003-0098-2238"},"route":"/people/alexis-cortot/","neighbours":{"cancer":[{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"},{"id":"sclc","kind":"cancer","name":"Small-cell lung cancer","route":"/cancers/sclc/"}],"company":[{"id":"ifct","kind":"company","name":"Intergroupe Francophone de Cancérologie Thoracique","route":"/companies/ifct/"}]}}